Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1) (ARTISTRY-1)

4 novembre 2026 mis à jour par: Gilead Sciences

Une étude de phase 2/3, randomisée, ouverte, multicentrique et contrôlée par un traitement actif, homogène sur le plan opérationnel, pour évaluer l'innocuité et l'efficacité du bictégravir/lénacapavir par rapport à un régime de base stable chez des personnes virologiquement supprimées atteintes du VIH-1 suivant des schémas thérapeutiques complexes stables

The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC) plus lenacapavir (LEN), versus current therapy (Phase 2) and BIC/LEN fixed-dose combination (FDC) versus current therapy (Phase 3) in people living with HIV (PWH).

Aperçu de l'étude

Type d'étude

Interventionnel

Inscription (Réel)

689

Phase

  • Phase 2
  • Phase 3

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

      • Cape Town, Afrique du Sud, 7925
        • Desmond Tutu Health Foundation Clinical Trials Unit
      • Ga-Rankuwa, Afrique du Sud, 208
        • Sefako Makgatho Health Sciences University
      • Johannesburg, Afrique du Sud, 2193
        • Ezintsha
      • Berlin, Allemagne, 10439
        • zibp Zentrum für Infektiologie Berlin Prenzlauer Berg GmbH
      • Bonn, Allemagne, 53127
        • Universitatsklinikum Bonn
      • Frankfurt, Allemagne, 60596
        • Infektio Research GmbH & Co.KG
      • Hamburg, Allemagne, 20146
        • ICH Study Center GmbH & Co. KG
      • München, Allemagne
        • MVZ München am Goetheplatz
      • Buenos Aires, Argentine, 1202
        • Fundación Huésped
      • Buenos Aires, Argentine, 1072
        • Hospital General de Agudos J.M Ramon Mejia
      • Buenos Aires, Argentine, 1425
        • Helios Salud
    • New South Wales
      • Darlinghurst, New South Wales, Australie, 2010
        • St.Vincent's Hospital Sydney
      • Darlinghurst, New South Wales, Australie, 2011
        • Taylor Square Private Clinic
      • Sydney, New South Wales, Australie, 2010
        • Holdsworth House Medical Practice
    • Victoria
      • Melbourne, Victoria, Australie, 3004
        • Alfred Health
      • Decarie Montreal, Canada, H4A 3J1
        • Chronic Viral Illness Service / McGill University Health Centre (MUHC)
      • Montreal, Canada, H2L 0B1
        • Clinique Medicale du Quartier Latin
      • Ottawa, Canada, K1H 8L6
        • The Ottawa Hospital - General Campus
      • Regina, Canada, S4P 0W5
        • ID Clinic
      • Toronto, Canada, M5G 1K2
        • Maple Leaf Research
      • Vancouver, Canada, V6Z 2T1
        • Spectrum Health
      • Daegu, Corée du Sud, 41944
        • Kyungpook National University Hospital
      • Daejeon, Corée du Sud, 35015
        • Chungnam National University Hospital
      • Seoul, Corée du Sud, 06591
        • The Catholic University of Korea Seoul St. Mary's Hospital
      • Seoul, Corée du Sud, 03722
        • Yonsei University Severance Hospital
      • Barcelona, Espagne, 08036
        • Hospital Clinic Provincial de Barcelona
      • Madrid, Espagne, 28040
        • Hospital Clinico San Carlos
      • Madrid, Espagne, 28046
        • Hospital Universitario La Paz
      • Madrid, Espagne, 28034
        • Hospital Ramon y Cajal, Madrid
      • Seville, Espagne, 4103
        • Hospital Universitario Virgen del Rocio
      • Nice, France, 6202
        • CHU Nice-Hôpital l'Archet
      • Paris, France, 75010
        • Hospital Saint Louis
      • Paris, France, 75018
        • Groupe Hospitalier Bichat Claude Bernard
      • Paris, France, 75651
        • Höpital de la Pitié Salpêtrière
      • Milan, Italie, 20157
        • ASST Fatebenefratelli Sacco
      • Milan, Italie, 20127
        • IRCCS Ospedale San Raffaele
      • Modena, Italie, 40124
        • Azienda Ospedaliero-Universitaria di Modena
      • Roma, Italie, 00149
        • Istituto Nazionale Malattie Infettive "Lazzaro Spallanzani" IRCCS
      • Torino, Italie, 10149
        • ASL Città di Torino
      • Nagoya, Japon
        • National Hospital Organization Nagoya Medical Center
      • Osaka, Japon, 540-0006
        • National Hospital Organization Osaka National Hospital
      • Tokyo, Japon, 162-0052
        • Center Hospital of the National Center for Global Health and Medicine
    • PR
      • San Juan, PR, Porto Rico, 00909
        • Hope Clinical Research
      • San Juan, PR, Porto Rico, 00935
        • Proyecto ACTU
      • Birmingham, Royaume-Uni, B9 5SS
        • Department of HIV & Sexual Medicine
      • Brighton, Royaume-Uni, BN2 3EW
        • Brighton and Sussex University Hospitals NHS Trust
      • London, Royaume-Uni, E1 1BB.
        • Barts Health NHS Trust
      • London, Royaume-Uni, SE5 9RS
        • HIV medicine and infectious diseases
      • London, Royaume-Uni, SW109NH
        • St.Stephen's AIDS Trust, Clinical Trials Unit, 1st Floor, St.Stephen's Centre
      • Santo Domingo, République Dominicaine
        • Instituto Dominicano de Estudio Virologicos - IDEV
      • Kaohsiung City, Taïwan, 80756
        • Kaohsiung Medical University Chung-Ho Memorial Hospital
      • Kaohsiung City, Taïwan, 81362
        • Kaohsiung Medical University Chung-Ho Memorial Hospital
      • New Taipei City, Taïwan, 22060
        • Far Eastern Memorial Hospital
      • Taoyuan City, Taïwan, 33004
        • Taoyuan General Hospital
    • California
      • Berkeley, California, États-Unis, 48072
        • Be Well Medical Center
      • Beverly Hills, California, États-Unis, 90211
        • Pacific Oaks Medical Group
      • Los Angeles, California, États-Unis, 90036
        • Ruane Clinical Research Group, Inc
      • Oakland, California, États-Unis, 94609
        • Alta Bates Summit Medical Center, Summit Campus, East Bay Advanced Care
      • Palm Springs, California, États-Unis, 92262
        • Bios Clinical Research
      • San Diego, California, États-Unis, 92103
        • University of California San Diego (UCSD)
      • Torrance, California, États-Unis, 90502
        • Lundquist Institute for Biomedical Innovation at Harbor - UCLA Medical Center
      • West Hollywood, California, États-Unis, 90046
        • The Men's Health Foundation
    • Colorado
      • Denver, Colorado, États-Unis, 80204
        • Denver Health Medical Center
    • Connecticut
      • New Haven, Connecticut, États-Unis, 06510
        • Yale University; School of Medicine; AIDS Program
    • Florida
      • DeLand, Florida, États-Unis, 32720
        • Midland Florida Clinical Research Center, LLC
      • Fort Lauderdale, Florida, États-Unis, 33316
        • Gary Richmond, MD, PA, Inc.
      • Fort Lauderdale, Florida, États-Unis, 33308
        • Therafirst Medical Centers
      • Ft. Pierce, Florida, États-Unis, 34982
        • Midway Immunology & Research Center, LLC
      • Miami, Florida, États-Unis, 33136
        • Schiff Center for liver Diseases/University of Miami
      • Miami Lakes, Florida, États-Unis, 33016
        • Floridian Clinical Research
      • Orlando, Florida, États-Unis, 32803
        • Orlando Immunology Center
      • Orlando, Florida, États-Unis, 32803
        • Therapeutic Concepts, PA
      • West Palm Beach, Florida, États-Unis, 33407
        • Triple O Research Institute PA
    • Georgia
      • Atlanta, Georgia, États-Unis, 30309
        • Atlanta ID Group
      • Macon, Georgia, États-Unis, 31201
        • Mercer University School of Medicine
    • Illinois
      • Chicago, Illinois, États-Unis, 60613
        • Howard Brown Health Center
    • Missouri
      • Kansas City, Missouri, États-Unis, 64111
        • Kansas City Care Clinic
      • St Louis, Missouri, États-Unis, 63139
        • Southampton Healthcare, Inc.
    • New Jersey
      • Newark, New Jersey, États-Unis, 07102
        • Saint Michael's Medical Center
    • New Mexico
      • Santa Fe, New Mexico, États-Unis, 87505
        • AXCES Research Group
    • New York
      • Flushing, New York, États-Unis, 11355
        • New York Presbyterian Hospital
      • New York, New York, États-Unis, 10001
        • Ricky K. Hsu, MD, PC
    • North Carolina
      • Chapel Hill, North Carolina, États-Unis, 27514
        • University of North Carolina - Chapel Hill
      • Greenville, North Carolina, États-Unis, 27858
        • East Carolina University
    • Pennsylvania
      • Philadelphia, Pennsylvania, États-Unis, 19107
        • Philadelphia FIGHT
    • South Carolina
      • Charleston, South Carolina, États-Unis, 29425
        • Medical University of South Carolina (MUSC) Research NEXUS
    • Texas
      • Austin, Texas, États-Unis, 78705
        • Central Texas Clinical Research
      • Bellaire, Texas, États-Unis, 77401
        • St. Hope Foundation
      • Dallas, Texas, États-Unis, 75246
        • North Texas Infectious Diseases Consultants
      • Dallas, Texas, États-Unis, 75208
        • AIDS Arms, Inc., DBA Prism Health North Texas
      • Fort Worth, Texas, États-Unis, 76104
        • Texas Centers for Infectious Disease Associates
      • Houston, Texas, États-Unis, 77098
        • Gordon E. Crofoot MD PA
      • Longview, Texas, États-Unis, 75605
        • Diagnostic Clinic of Longview - Center for Clinical Research
    • Washington
      • Seattle, Washington, États-Unis, 98104
        • Peter Shalit, MD

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Key Inclusion Criteria:

  • If plasma HIV-1 RNA measurements in the 6 months prior to screening are available, all levels must be < 50 copies/mL.

  • At least one documented plasma HIV-1 RNA level measured between 6 and 12 months (± 2 months) prior to screening. This and any other HIV-1 RNA measurements documented in this period must be < 50 copies/mL

  • Plasma HIV-1 RNA levels < 50 copies/mL at screening.

  • Currently receiving a complex antiretroviral (ARV) regimen due to previous viral resistance, or intolerance, or contraindication to existing single-tablet regimens (STR), and on this regimen for at least 6 months prior to the screening visit. The criteria to define a complex regimen in this study are as follows:

    • A regimen containing a boosted protease inhibitor or a nonnucleos(t)ide reverse transcriptase inhibitor (NRTI) plus at least 1 other third agent (ie, an agent from a class other than NRTIs) (eg, bictegravir/emtricitabine/tenofovir alafenamide (coformulated; Biktarvy®)(BVY) + darunavir/cobicistat, BVY + etravirine), or
    • A regimen of ≥ 2 pills/day, or a regimen requiring dosing more than once daily, or
    • A regimen containing parenteral agent(s) (excluding a complete long-acting injectable regimen, such as intramuscular cabotegravir plus rilpivirine) as well as oral agents.
  • No documented or suspected resistance to bictegravir (BIC).

  • Estimated glomerular filtration rate ≥ 15 mL/min according to the Cockcroft-Gault formula for creatinine clearance (CLcr) who are not on renal replacement therapy.

Key Exclusion Criteria:

  • Prior use of, or exposure to, lenacapavir (LEN)
  • Active tuberculosis infection
  • Chronic hepatitis B virus (HBV) infection

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Phase 2: Treatment Group 1: BIC 75 mg + LEN 25 mg

Participants will switch from their Stable Baseline Regimen (SBR) to a regimen of BIC 75 mg + LEN 25 mg, tablets administered orally once daily for up to 24 weeks. Participants will receive a 2-day pharmacokinetic (PK) oral loading dose of LEN 600 mg, on Days 1 and 2, in addition to the daily doses of BIC 75 mg + LEN 25 mg starting on Day 1.

Participants who discontinue early or complete the Randomized Phase (RP) will have an option to continue in Extension Period (EP)

Tablets administered orally without regard to food

Autres noms:
  • GS-6207

Tablets administered orally without regard to food

Autres noms:
  • GS-9883
Expérimental: Phase 2: Treatment Group 2: BIC 75 mg + LEN 50 mg

Participants will switch from their SBR to a regimen of BIC 75 mg + LEN 50 mg, tablets administered orally once daily for up to 24 weeks. Participants will receive a 2-day PK oral loading dose of LEN 600 mg, on Days 1 and 2, in addition to the daily doses of BIC 75 mg + LEN 50 mg starting on Day 1.

Participants who discontinue early or complete the RP will have an option to continue in EP.

Tablets administered orally without regard to food

Autres noms:
  • GS-6207

Tablets administered orally without regard to food

Autres noms:
  • GS-9883
Comparateur actif: Phase 2: Treatment Group 3: SBR

Participants will continue with their SBR for up to 24 weeks.

Participants who discontinue early or complete the RP will have an option to continue in EP.

SBR will include a combination of antiretroviral (ARV) regimen. ARV regimen may include the following, except for participants taking a single tablet regimen or taking a complete parenteral regimen (Cabenuva).

  • Nucleos(t)ide Reverse Transcriptase Inhibitors:

    • Abacavir
    • Emtricitabine
    • Lamivudine
    • Tenofovir alafenamide
    • Tenofovir disoproxil fumarate
    • Zidovudine
  • Non-Nucleosite Reverse Transcriptase Inhibitors:

    • Delavirdine
    • Efavirenz
    • Nevirapine
    • Rilpivirine
    • Doravirine
  • Integrase Inhibitors:

    • Bictegravir
    • Cabotegravir
    • Dolutegravir
    • Elvitegravir
    • Raltegravir
  • Protease Inhibitors:

    • Atazanavir
    • Darunavir
    • Fosamprenavir
    • Indinavir
    • Lopinavir
    • Nelfinavir
    • Saquinavir
    • Tipranavir
  • Chemokine Co-receptor 5 (CCR5) Antagonist:

    • Maraviroc
  • Fusion Inhibitors:

    • Enfuvirtide
  • gp120 Attachment Inhibitor:

    • Fostemsavir
  • Anti-CD4 Monoclonal Antibodies:

    • Ibalizumab-uiyk
Expérimental: Phase 3: Treatment Group 1: BIC/LEN 75 mg/50 mg FDC

Participants will switch from their SBR to a regimen of BIC/LEN 75mg/50mg FDC, administered orally once daily for up to 48 weeks. Participants will receive a 2-day PK oral loading dose of LEN 600 mg, on Days 1 and 2, in addition to the daily doses of BIC/LEN 75 mg/50 mg FDC starting on Day 1.

Participants who discontinue early or complete the RP will have an option to continue in EP.

Tablets administered orally without regard to food

Autres noms:
  • Bixlenvo™
Comparateur actif: Phase 3: Treatment Group 2: SBR

Participants will continue with their SBR for up to 48 weeks.

Participants who will discontinue early or complete the RP had an option to continue in EP.

SBR will include a combination of antiretroviral (ARV) regimen. ARV regimen may include the following, except for participants taking a single tablet regimen or taking a complete parenteral regimen (Cabenuva).

  • Nucleos(t)ide Reverse Transcriptase Inhibitors:

    • Abacavir
    • Emtricitabine
    • Lamivudine
    • Tenofovir alafenamide
    • Tenofovir disoproxil fumarate
    • Zidovudine
  • Non-Nucleosite Reverse Transcriptase Inhibitors:

    • Delavirdine
    • Efavirenz
    • Nevirapine
    • Rilpivirine
    • Doravirine
  • Integrase Inhibitors:

    • Bictegravir
    • Cabotegravir
    • Dolutegravir
    • Elvitegravir
    • Raltegravir
  • Protease Inhibitors:

    • Atazanavir
    • Darunavir
    • Fosamprenavir
    • Indinavir
    • Lopinavir
    • Nelfinavir
    • Saquinavir
    • Tipranavir
  • Chemokine Co-receptor 5 (CCR5) Antagonist:

    • Maraviroc
  • Fusion Inhibitors:

    • Enfuvirtide
  • gp120 Attachment Inhibitor:

    • Fostemsavir
  • Anti-CD4 Monoclonal Antibodies:

    • Ibalizumab-uiyk
Expérimental: Phase 2/Phase 3:BIC/LEN 75/50 mg FDC

At the end of randomized treatment, participants in Phase 2 and Phase 3 treatment groups who discontinue early or complete the RP will be given an option to enter in EP and will receive BIC/LEN 75/50 mg FDC until the drug is available in market or Gilead elects to withdraw the study. Participants in the SBR groups (Phase 2 Treatment Group 3 and Phase 3 Treatment Group 2 will also receive a 2-day PK oral loading dose of LEN 600 mg, on Days 1 and 2 of EP).

Tablets administered orally without regard to food

Autres noms:
  • GS-6207

Tablets administered orally without regard to food

Autres noms:
  • Bixlenvo™

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Phase 2: Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) ≥ 50 Copies/mL at Week 24 as Determined by the United States Food and Drug Administration (US FDA) Defined Snapshot Algorithm
Délai: Week 24

Participants who had the last available on-treatment HIV-1 RNA≥ 50 copies/mL in the week 24 analysis window, or who did not have on-treatment HIV-1 RNA data in the week 24 analysis window and participants who discontinued study drug prior to or in the week 24 analysis window due to lack of efficacy, or who discontinued study drug prior to or in the week 24 analysis window due to adverse event (AE) or death and have the last available on-treatment HIV-1 RNA≥ 50 copies/mL, or who discontinued study drug prior to or in the week 24 analysis window due to reasons other than AE, death, or lack of efficacy and have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL were included. The Week 24 window for snapshot algorithm was between Days 127 and 210 (inclusively). Percentages were rounded off.

Week 24
Phase 3: Percentages of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm
Délai: Week 48

Participants who had the last available on-treatment HIV-1 RNA ≥ 50 copies/mL in the Week 48 analysis window, or who did not have on-treatment HIV-1 RNA data in the Week 48 analysis window and who discontinued study drug prior to or in the Week 48 analysis window due to lack of efficacy, or who discontinued study drug prior to or in the Week 48 analysis window due to AE or death and have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL, or who discontinued study drug prior to or in the Week 48 analysis window due to reasons other than AE, death, or lack of efficacy and have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL were included. The Week 48 window for snapshot algorithm was between Days 295 and 378 (inclusively). Percentages were rounded off.

Week 48

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Phase 2: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 as Determined by the US FDA-defined Snapshot Algorithm
Délai: Week 24

Participants who had the last available on-treatment HIV-1 RNA < 50 copies/mL in the Week 24 analysis window were included. The Week 24 window for snapshot algorithm was between Days 127 and 210 (inclusively). Percentages were rounded off.

Week 24
Phase 2: Change From Baseline in Clusters of Differentiation 4 (CD4) Cell Count at Week 24
Délai: Baseline, Week 24
Baseline, Week 24
Phase 2: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) Through Week 24
Délai: First dose date up to Week 24

An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment. TEAEs were defined as any AE that begins on or after the date of first dose of study drug up to the date of last dose of study drug plus 60 days (for BIC+LEN or BIC/LEN FDC) or 30 days (for SBR) or any AE leading to study drug discontinuation. Percentages were rounded off.

First dose date up to Week 24
Phase 2: PK Parameter: Cmax for Bictegravir (BIC) at Steady State
Délai: At Week 16 or 24

Cmax is defined as the maximum observed concentration of drug. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.

At Week 16 or 24
Phase 2: PK Parameter: Cmax for Lenacapavir (LEN) at Steady State
Délai: At Week 16 or Week 24

Cmax is defined as the maximum observed concentration of drug. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.

At Week 16 or Week 24
Phase 2: PK Parameter: AUCtau of BIC at Steady State
Délai: At Week 16 or 24

AUCtau is defined as the area under the concentration versus time curve over the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.

At Week 16 or 24
Phase 2: PK Parameter: AUCtau for LEN at Steady State
Délai: At Week 16 or Week 24

AUCtau is defined as the area under the concentration versus time curve over the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.

At Week 16 or Week 24
Phase 2: PK Parameter: Ctrough of BIC at Steady State
Délai: At Week 16 or Week 24

Ctrough is defined as the observed drug concentration at the end of the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.

At Week 16 or Week 24
Phase 2: PK Parameter: Ctrough of LEN at Steady State
Délai: At Week 16 or Week 24

Ctrough is defined as the observed drug concentration at the end of the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.

At Week 16 or Week 24
Phase 3: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm
Délai: Week 48

Participants who had the last available on-treatment HIV-1 RNA < 50 copies/mL in the Week 48 analysis window were included. The Week 48 window for snapshot algorithm was between Days 295 and 378 (inclusively).

Week 48
Phase 3: Change From Baseline in CD4 Cell Count at Week 48
Délai: Baseline, Week 48

An AE was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment. TEAEs were defined as any AE that begins on or after the date of first dose of study drug up to the date of last dose of study drug plus 60 days (for BIC+LEN or BIC/LEN FDC) or 30 days (for SBR) or any AE leading to study drug discontinuation. Percentages were rounded off.

Baseline, Week 48
Phase 3: Percentage of Participants Experiencing TEAEs Through Week 48
Délai: First dose date up to Week 48

An AE was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment. TEAEs were defined as 1 or both of the following: Any AEs leading to premature discontinuation of study drug, or any AEs with an onset date on or after the study drug start date and no later than the last exposure date after permanent discontinuation of the study drug. Percentages were rounded off.

First dose date up to Week 48
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 96 as Determined by the US FDA-defined Snapshot Algorithm
Délai: Week 96
Week 96
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 144 as Determined by the US FDA-defined Snapshot Algorithm
Délai: Week 144
Week 144
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 as Determined by the US FDA-defined Snapshot Algorithm
Délai: Week 96
Week 96
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 144 as Determined by the US FDA-defined Snapshot Algorithm
Délai: Week 144
Week 144
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Change From Baseline in CD4 Cell Count at Week 96
Délai: Baseline, Week 96
Baseline, Week 96
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Change From Baseline in CD4 Cell Count at Week 144
Délai: Baseline, Week 144
Baseline, Week 144
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants Experiencing TEAEs Through Week 96
Délai: Week 96
Week 96
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants Experiencing TEAEs Through Week 144
Délai: Week 144
Week 144

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

16 août 2022

Achèvement primaire (Réel)

29 septembre 2025

Achèvement de l'étude (Estimé)

1 décembre 2029

Dates d'inscription aux études

Première soumission

5 août 2022

Première soumission répondant aux critères de contrôle qualité

12 août 2022

Première publication (Réel)

16 août 2022

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

5 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

4 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Termes MeSH pertinents supplémentaires

Autres numéros d'identification d'étude

  • GS-US-621-6289
  • 2022-500929-33 (Autre identifiant: European Medicines Agency)
  • DOH-27-052023-8574 (Autre identifiant: South African Clinical Trial Registry)
  • jRCT2051230168 (Autre identifiant: Japan registry)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner